Source:http://linkedlifedata.com/resource/pubmed/id/10583392
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
3
|
pubmed:dateCreated |
2000-1-31
|
pubmed:abstractText |
The chimeric peptide [Lys(-2)-Arg(-1)]-sarafotoxin-S6b (KR-SRTb) designed from the Lys-2-Arg-1 dipeptide of the endothelin pro-sequence and the sarafotoxin-S6b sequence was synthesized. Its contractile activity was found to be decreased markedly when compared with that of the parent SRTb. In contrast, the extension by the Lys-Arg dipeptide was found to increase the formation of the native disulfide isomer (82/18 versus 96/4) when the reaction was carried out in the presence of redox reagents. The solution structure of KR-SRTb was determined by NMR as a function of pH. In the carboxylic acid state, the structure consists of the cystine-stabilized alpha-helical motif, with the alpha-helical part spanning residues 9-15, and of an unstructured C-terminal tail. In the carboxylate state, the structure is characterized by a salt-bridge between Arg(-1) and Asp8, which we identified previously in the [Lys(-2)-Arg(-1)]-endothelin-1 peptide (KR-ET-1). The fact that this salt-bridge is commonly observed in KR-SRTb and KR-ET-1, despite the 33% sequence difference between the corresponding parental peptides, highlights the remarkable adaptability of the Lys-Arg extension for the formation of a special salt-bridge. As a consequence, this salt-bridge, which does not depend on either the 4-7 sequence of the loop or the C-terminal sequence, appears to be particularly well suited to improve the stability of the cystine-stabilized alpha-helical motif. Therefore, because of its high yield in the native disulfide arrangement and its high permissiveness for sequence mutation in the 4-7 loop, such a stabilized cystine-stabilized alpha-helical motif could be a valuable scaffold for the presentation of a library of constrained short peptides.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Disulfides,
http://linkedlifedata.com/resource/pubmed/chemical/Endothelin-1,
http://linkedlifedata.com/resource/pubmed/chemical/Recombinant Fusion Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/Salts,
http://linkedlifedata.com/resource/pubmed/chemical/Vasoconstrictor Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Viper Venoms,
http://linkedlifedata.com/resource/pubmed/chemical/sarafotoxins s6
|
pubmed:status |
MEDLINE
|
pubmed:month |
Dec
|
pubmed:issn |
0014-2956
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
266
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
977-85
|
pubmed:dateRevised |
2007-7-23
|
pubmed:meshHeading |
pubmed-meshheading:10583392-Amino Acid Sequence,
pubmed-meshheading:10583392-Animals,
pubmed-meshheading:10583392-Disulfides,
pubmed-meshheading:10583392-Endothelin-1,
pubmed-meshheading:10583392-Magnetic Resonance Spectroscopy,
pubmed-meshheading:10583392-Models, Molecular,
pubmed-meshheading:10583392-Molecular Sequence Data,
pubmed-meshheading:10583392-Oxidation-Reduction,
pubmed-meshheading:10583392-Protein Structure, Secondary,
pubmed-meshheading:10583392-Rats,
pubmed-meshheading:10583392-Recombinant Fusion Proteins,
pubmed-meshheading:10583392-Salts,
pubmed-meshheading:10583392-Structure-Activity Relationship,
pubmed-meshheading:10583392-Vasoconstrictor Agents,
pubmed-meshheading:10583392-Viper Venoms
|
pubmed:year |
1999
|
pubmed:articleTitle |
The chimeric peptide [Lys(-2)-Arg(-1)]-sarafotoxin-S6b, composed of the endothelin pro-sequence and sarafotoxin, retains the salt-bridge staple between Arg(-1) and Asp8 previously observed in [Lys(-2)-Arg(-1)]-endothelin. Implications of this salt-bridge in the contractile activity and the oxidative folding reaction.
|
pubmed:affiliation |
Centre de Biochimie Structurale, CNRS UMR C9955, INSERM U414, Faculté de Pharmacie, Montpellier, France. aumelas@cbs.univ-montp1.fr
|
pubmed:publicationType |
Journal Article,
Comparative Study,
In Vitro
|